FindMeCure Widget Medical science has been rapidly advancing in the recent decades and we can prove that with many examples: new therapies for diabetes, the first vaccine for the prevention of cervical cancer, oral treatments for Hepatitis C curing more than 90% of the cases, the first Lupus drug in 50 years, personalized medicines to treat the most dangerous types of skin cancer, genome editing, immunotherapy eradicating cancer cells, and many many more. And we all remember the end of AIDS and how medicine turned the HIV infection into a chronic condition that no longer threatens one’s life. Ask scientists [...]
#MoveForMigraine Migraine remains an overlooked and misunderstood condition in many parts of Europe, including Belgium. The disease suffers from a lack of recognition and understanding, even from the first concerned parties (patients, caregivers, employers, etc.). This comes at a significant burden for the patients and at a high cost for society (1,650,000 working days lost every year in Belgium). #Move4Migraine is an independent, multidisciplinary platform that brings patients and actors from the healthcare, labour world and civil society together. Mik Ver Berne, chair of the Belgian Headache Association and member of the European Migraine Headache Alliance (EMHA), participates in the [...]
INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month. TM In June 2018, Lilly announced the intended brand name, Emgality, was conditionally accepted by the U.S. Food and Drug Administration (FDA). Emgality is a humanized monoclonal antibody specifically designed to bind to the calcitonin gene-related peptide (CGRP), blocking its [...]
Active Citizenship Network launch the second edition of the bi-annual research-project at the European level “EU Civic Prize on Chronic Pain - Collection of good practices” with the aim to continue to give evidence on existing good practices in several European countries in terms of the struggle against pain. Aims of the project Giving continuity to the successful collection of good practices “EU Civic Prize on Chronic Pain - Collection of good practices” - First Edition. Enriching European and national experiences, expertise, data and benchmarking on chronic pain. Fostering the multi-stakeholder platform of operators of good practices on pain, created in [...]
On Friday 7 December 2018, patient advocates and stakeholders from all world regions will stand together, united in a celebration of Patient Solidarity Day (PSD). This year’s theme is about ‘Safe Medication and Healthcare for All’ and it aims to raise awareness on these critical global public health issues and advocate for access to safe, quality and appropriate medicines and treatments as warranted by patients' conditions. The Key Messages about Patient Solidarity Day: This Patient Solidarity Day patient advocates across the globe are coming together in solidarity to raise awareness on and advocate for access to safe medication and healthcare for all. Patient exposure [...]
INDIANAPOLIS, Sept. 27, 2018 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available to patients shortly after approval. Patients with commercial insurance are candidates to receive Emgality for up to 12 months free as part of Lilly's patient support program (governmental beneficiaries excluded; subject to terms and conditions*). Emgality will be available for pickup at retail pharmacies. Migraine [...]
European Migraine and Headache Alliance (EMHA) has launched a new version of its corporate website: www.emhalliance.org The website has a number of new features to improve user experience, including: A complete refreshed homepage where we have implemented a calendar in which users can see the great activity of EMHA for every month, all the congresses, events, meetings and acts we will be assisting to. A new slider which shows the events we have participated in with a brief description A new space called EMHAnews (in substitution of EMHA Magazine) in which we will be updating more internal news of the organization [...]
EMHA assists to the 12th European Headache Federation Congress in Florence. 1.000 Neurologists today discussing over migraine, new treatments, the sub origin of migraine, it's future and the EMHA present at the event always trying to give a voice to patients and spread the word!
This month of September is being extremely busy and we are traveling to support, defend and activate the Patients everywhere !!. EMHA Executive Director Mrs. Elena Ruiz de la Torre travels to Mexico in order to assist the first international congress done in Puebla (Mexico) organized by Mexican Cluster and Migraine Association (AMCEMIG). Her speech will be focused on her personal experience as a migraineur and how it affects her daily life activities. Find below some images of Mrs. Elena Ruiz de la Torre speaking to Mexican Patients and Neurologists.
EMHA Executive Director Mrs. Elena Ruiz de la Torre traveled to Greece yesterday September 12th on Migraine Day of Action, to assist to the meeting held at Athens by the Hellenic Headache Society on behalf of Migraine Awareness Day. She had the chance to tell her personal story about being a migraineur and how it has impacted her life, in front of people like General Secretary of Social Security, Mr. Vraka, of Mr. Mitsikostas, President of the Greek Headache Federation, and of the President of the Greek Migraine and Headache.